Assignee
IMMODULON THERAPEUTICS LTD
GB·11 granted patents·12 pending applications·32 citations·filing 2012–2024
Top patents by PatentIndex Score
23 records- 0193US11318193B2Immunogenic treatment of cancerIMMODULON THERAPEUTICS LTD·Filed 2018·Granted May 3, 2022·9 cites·12 claims
- 0291US11554166B2Immunogenic treatment of cancerIMMODULON THERAPEUTICS LTD·Filed 2020·Granted Jan 17, 2023·3 cites·14 claims
- 0390US10610578B2Checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapyIMMODULON THERAPEUTICS LTD·Filed 2018·Granted Apr 7, 2020·7 cites·16 claims
- 0487US10610577B2Checkpoint inhibitor and a whole cell Mycobacterium for use in cancer therapyIMMODULON THERAPEUTICS LTD·Filed 2014·Granted Apr 7, 2020·7 cites·13 claims
- 0587US2025170231A1Checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapyIMMODULON THERAPEUTICS LTD·Filed 2024·Application pending·0 cites
- 0684US11000584B2Checkpoint inhibitor and a whole cell Mycobacterium for use in cancer therapyIMMODULON THERAPEUTICS LTD·Filed 2020·Granted May 11, 2021·1 cites·20 claims
- 0784US10994002B2Checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapyIMMODULON THERAPEUTICS LTD·Filed 2020·Granted May 4, 2021·1 cites·20 claims
- 0884US10925952B2Checkpoint inhibitor and a whole cell Mycobacterium for use in cancer therapyIMMODULON THERAPEUTICS LTD·Filed 2020·Granted Feb 23, 2021·1 cites·20 claims
- 0977US2023149525A1Immunogenic treatment of cancerIMMODULON THERAPEUTICS LTD·Filed 2023·Application pending·0 cites
- 1075US12042532B2Checkpoint inhibitor and a whole cell Mycobacterium for use in cancer therapyIMMODULON THERAPEUTICS LTD·Filed 2021·Granted Jul 23, 2024·0 cites·17 claims
- 1174US10071124B2Treatment of post-traumatic stress disorder with isolated MycobacteriumIMMODULON THERAPEUTICS LTD·Filed 2013·Granted Sep 11, 2018·2 cites·12 claims
- 1269US11207405B2Checkpoint inhibitor and a whole cell Mycobacterium for use in cancer therapyIMMODULON THERAPEUTICS LTD·Filed 2016·Granted Dec 28, 2021·1 cites·18 claims
- 1365US10736864B2Immunotherapeutic agentIMMODULON THERAPEUTICS LTD·Filed 2019·Granted Aug 11, 2020·0 cites·3 claims
- 1462US2022111046A1Checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapyIMMODULON THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 1556US2020297680A1Immunotherapeutic agentIMMODULON THERAPEUTICS LTD·Filed 2020·Application pending·0 cites
- 1655US2018185317A1Immunotherapeutic agentIMMODULON THERAPEUTICS LTD·Filed 2017·Application pending·0 cites
- 1755US2014356397A1Immunogenic Treatment Of CancerIMMODULON THERAPEUTICS LTD·Filed 2012·Application pending·0 cites
- 1850US2023050258A1Immunotherapeutic treatment of cancerIMMODULON THERAPEUTICS LTD·Filed 2020·Application pending·0 cites
- 1947US2024216443A1A mycobacterium for use in cancer therapyIMMODULON THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 2047US2023405114A1Mycobacterial immunotherapy for treating cancerIMMODULON THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 2144US2023405059A1A mycobacterium for use in cancer therapyIMMODULON THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 2244US2023084300A1Prevention and treatment of infections including those caused by coronavirusIMMODULON THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 2340US2021299187A1Cancer therapyIMMODULON THERAPEUTICS LTD·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when IMMODULON THERAPEUTICS LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →